Digital health companies DarioHealth Corp (NASDAQ: DRIO) and OneStep announced on Monday a strategic collaboration to integrate smartphone-based, clinical-grade fall risk assessment technology into Dario's multi-condition digital health platform. The partnership aims to deliver measurable return on investment for health plans by reducing falls and improving outcomes among high-risk populations, including those with obesity and Medicare Advantage members experiencing frailty and balance issues.
Under a signed Memorandum of Understanding, with a Master Services Agreement expected shortly, Dario will incorporate OneStep's FDA-listed motion analysis technology to provide proactive fall risk identification and education. The integration will enable at-risk users to access real-time insights that support fall prevention and reduce related healthcare costs.
Falls generate more than USD50bn annually in direct medical expenses in the US, according to the Centers for Disease Control and Prevention, with Medicare and Medicaid covering around 75% of the total. The US fall management market, valued at nearly USD200m in 2024, is projected to exceed USD300m by 2033, reflecting a compound annual growth rate of more than 5%.
DarioHealth provides a multi-condition platform for chronic disease management across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
OneStep's smartphone-based gait analysis technology delivers clinical mobility insights to support fall prevention and remote patient monitoring.
Alto Neuroscience receives FDA Fast Track designation for ALTO-101
Calico Life Sciences' investigational treatment for ADPKD receives US FDA Fast Track Designation
Hologic receives FDA clearance and CE mark for new gastrointestinal bacterial assays
Celltrion launches AVTOZMA IV in the United States following FDA approval
Vanda Pharmaceuticals agrees collaborative framework to resolve US FDA disputes
Microbot Medical secures first Japanese patent for Liberty robotic system following FDA clearance
Pharming receives FDA priority review for leniolisib in children with APDS
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe